A

    Alto Neuroscience, Inc. (ANRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $35.34
    +0.21 (+0.60%)

    Market Cap: $1.38B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(7/11)
    Avg Surprise
    -37.37%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.70
    Range$-0.89 - $-0.60
    7 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.76-7.8%
    60d ago$-0.80-13.6%
    30d ago$-0.80-13.6%
    7d ago$-0.80-13.6%
    Current$-0.70
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.94
    Range$-1.35 - $-0.63
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.94---
    Sep 26EST
    		-$-0.70---
    Jun 26
    		$-0.65$-0.71+8.45%Beat+0.0%
    Mar 26
    		$-0.80$-0.50-60.00%Miss-42.9%
    Dec 25
    		$-0.45$-0.66+31.82%Beat+13.5%
    Sep 25
    		$-0.52$-0.64+18.75%Beat+16.1%
    Jun 25
    		$-0.65$-0.60-8.33%Miss-8.3%
    Mar 25
    		$-0.56$-0.62+9.68%Beat+26.3%
    Dec 24
    		$-0.52$-0.55+5.45%Beat+93.3%
    Sep 24
    		$-0.62$-0.64+3.13%Beat-
    Jun 24
    		$-0.60$-0.67+10.45%Beat-
    Mar 24
    		$-0.76$-0.46-65.22%Miss-
    Dec 23
    		$-7.77$-1.67-365.27%Miss-

    Key Metrics

    Valuation
    P/E Ratio-14.60EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-49.20%ROIC-25.47%
    Financial Health
    Debt/Equity0.02xInterest Coverage-29.76x
    Current Ratio14.85xQuick Ratio14.85x
    Trading Statistics
    Beta1.09Avg Volume475.91K
    52-Week High$37.4852-Week Low$3.41

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$35.34
    SMA 20$32.55
    SMA 50$28.99
    SMA 200$21.79
    EMA 10$34.85
    EMA 20$33.09
    EMA 50$29.65
    EMA 200$21.90

    MACD

    Line: 2.28Signal: 2.18Hist: 0.10

    ADX

    ADX: 49.9+DI: 24.4-DI: 10.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$37.48

    Bollinger Bands

    Upper Band$39.07
    Lower Band$26.04
    %B Position4005%(Upper)
    Band Width0.71

    RSI (14-Day)

    Neutral
    68.1

    Momentum Oscillators

    Stoch %K80.6
    Stoch %D84.9
    Williams %R-23.2
    ROC (10d)5.2%
    Momentum1.74
    CCI (20d)62.1
    MFI (14d)66.4

    Volatility Measures

    ATR (14d)$1.95(5.5%)
    StdDev (20d)3.26
    Hist Vol48.4%(High)

    Volume Flow

    VWAP$35.05
    OBV105.0M
    AD Line31.5M
    CMF (20d)0.364

    Volume Metrics

    Avg Vol (20d)479.3K
    Vol Ratio1.6x(High)
    VWMA (20d)$32.85

    Pivot Points

    R3$36.65
    R2$36.18
    R1$35.66
    Pivot Point$35.19
    S1$34.67
    S2$34.20
    S3$33.68

    Advanced Oscillators

    TSI43.46
    Ultimate Osc62.5
    KST270.25

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$394,000$0$0$0$372,000$0
    Cost of RevenueN/A$184,000$157,000$164,000$100,000$171,000$170,000$200,000$100,000$97,000$92,000$95,000
    Gross ProfitN/A$-184,000$-157,000$-164,000$-100,000$-171,000$-170,000$-200,000$-100,000$-97,000$-92,000$-467,000
    Operating Expenses$29.13M$26.95M$-115,673,000$14.95M$18.58M$15.68M$16.83M$18.89M$18.34M$14.29M$11.67M$9.72M
    R&D$22.11M$20.29M$12.00M$10.53M$13.12M$9.97M$10.80M$13.06M$13.18M$9.95M$9.64M$7.97M
    SG&A$7.02M$6.84M$5.06M$4.43M$5.56M$5.70M$6.20M$5.83M$5.16M$4.43M$2.12M$1.75M
    Operating Income$-29,129,000$-27,138,000$115.67M$-14,951,000$-18,682,000$-15,676,000$-16,997,000$-18,886,000$-18,341,000$-14,386,000$-11,765,000$-9,718,000
    Interest Income$0$1.56M$1.56M$1.53M$1.68M$1.83M$2.13M$2.50M$2.66M$1.56M$738,000$714,000
    Interest Expense$491,000$545,000$575,000$650,000$646,000$598,000$333,000$349,000$347,000$346,000$356,000$363,000
    Income Before Tax$-27,638,000$-26,237,000$-16,182,000$-14,181,000$-17,706,000$-15,169,000$-15,201,000$-16,783,000$-16,030,000$-13,417,000$-11,217,000$-9,141,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-1$0$-363,000$363,000
    Net Income$-27,638,000$-26,237,000$-16,182,000$-14,181,000$-17,706,000$-15,169,000$-15,201,000$-16,783,000$-16,030,000$-13,417,000$-11,217,000$-9,141,000
    EBITDA$-27,147,000$-25,508,000$-15,450,000$-13,367,000$-16,960,000$-14,400,000$-14,698,000$-16,312,000$-15,570,000$-12,974,000$-10,769,000$-8,715,000
    EBITN/A$-25,692,000$-15,607,000$-13,531,000$-17,060,000$-14,571,000$-14,868,000$-16,434,000$-15,683,000$-13,071,000$-10,861,000$-8,778,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANRO

    News

    Alto Neuroscience stock hits all-time high at 35.42 USD

    Alto Neuroscience Inc.'s stock reached an all-time high of $35.42 USD, pushing its market capitalization to $1.38 billion, driven by a nearly 800% increase over the past year. While investor confidence is high, an InvestingPro analysis suggests the stock might be overvalued. Recent positive developments include a $100 million stock offering, promising clinical trial results for a mood disorder treatment, a raised price target from H.C. Wainwright, and the appointment of Andrew Miller, Ph.D., to its Board of Directors.

    Investing.com•8/25/26•
    Bullish

    Alto Neuroscience stock hits all-time high at 35.42 USD By Investing.com

    Alto Neuroscience Inc.'s stock reached an all-time high of $35.42, achieving a market capitalization of $1.38 billion, driven by a nearly 800% one-year return. The company recently announced a $100 million stock offering and shared positive clinical trial results for pramipexole in mood disorders, alongside a raised price target from H.C. Wainwright and the appointment of Andrew Miller to its Board of Directors.

    Investing.com South Africa•8/24/26•
    Bullish

    H.C. Wainwright raises Alto Neuroscience price target to $55

    H.C. Wainwright has increased its price target for Alto Neuroscience (NYSE:ANRO) to $55 from $50, maintaining a Buy rating. This adjustment follows Alto's announcement of its Q2 2026 results and the naming of its ALTO-207 development plan as the PACE program, which includes three trials for treatment-resistant depression. The firm also raised its probability of success for ALTO-207 in treatment-resistant depression to 35% from 30%, citing positive findings from an independent trial on pramipexole.

    Investing.com•8/18/26•
    Bullish

    H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55

    H.C. Wainwright has reiterated its Buy rating for Alto Neuroscience (ANRO.US) and maintained a target price of $55. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

    Moomoo•8/18/26•
    Bullish

    H.C. Wainwright raises Alto Neuroscience price target to $55

    H.C. Wainwright has increased its price target for Alto Neuroscience (NYSE:ANRO) to $55 from $50, maintaining a Buy rating, following the company's Q2 2026 results and the advancement of its ALTO-207 development plan (PACE program). The program includes three trials for treatment-resistant depression, with the PACE-1 Phase 2b study ongoing and PACE-2 and PACE-3 Phase 3 trials slated to begin in early to late 2027. The firm also cited supporting evidence from an independent trial published in Nature Medicine and raised ALTO-207's probability of success in treatment-resistant depression to 35%.

    Investing.com•8/18/26•
    Bullish

    Frequently Asked Questions About ANRO

    Does ANRO pay dividends?
    Alto Neuroscience, Inc. (ANRO) does not currently pay a regular dividend.
    What is ANRO's market cap?
    Alto Neuroscience, Inc. (ANRO) has a market capitalization of $1.38B with a current stock price of $35.34.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In